24 completed. 24 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 24 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow Encephalitis, Arbovirus: new trials by email Literature Review of Encephalitis, Arbovirus trials Research Report on Encephalitis, Arbovirus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults GBP560-A, GBP560-B, IXIARO - Japanese Encephalitis Virus Disease | Phase 1 / Phase 2 | Completed | SK Bioscience Co., Ltd. | 161 | 2025-02-24 | 2026-09-11 |
| Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age JEVAX, JECEVAX - Japanese Encephalitis | Phase 2 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | 220 | 2017-06-02 | 2018-09-17 |
| Safety and Immunogenicity of JECEVAX in Young Children JEVAX, JECEVAX-1, JECEVAX-0.8 - Japanese Encephalitis | Phase 2 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | 200 | 2015-04-01 | 2016-06-28 |
| New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly FSME-immune - Tick-borne Encephalitis | Phase 2 / Phase 3 | Completed | Sormland County Council, Sweden | 250 | 2015-01-01 | 2021-02-10 |
| Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients TBE virus vaccine - Tick Borne Encephalitis | Phase 2 | Completed | Medical University of Vienna | 34 | 2014-07-01 | 2022-02-03 |
| The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans Japanese Encephalitis vaccine, Yellow Fever vaccine - Yellow Fever, Encephalitis, Japanese | Phase 2 | Completed | Singapore General Hospital | 84 | 2013-10-01 | 2016-04-20 |
| Humoral Response to Tick-borne Encephalitis Vaccine in Elderly FSME-immune - Tick-borne Encephalitis | Phase 2 / Phase 3 | Completed | Sormland County Council, Sweden | 200 | 2011-09-01 | 2015-11-18 |
| Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)] - Japanese Encephalitis | Phase 2 | Completed | University of Liverpool | 22 | 2009-05-01 | 2013-05-21 |
| Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults ChimeriVax-WN02 vaccine, Placebo - West Nile Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 479 | 2008-10-01 | 2015-04-03 |
| Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine Inactivated, Dried, TSI-GSD 104, EEE - Eastern Equine Encephalitis | Phase 2 | Completed | U.S. Army Medical Research and Development Command | 138 | 2008-06-03 | 2019-09-24 |
| Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104 - Eastern Equine Encephalitis | Phase 2 | Completed | U.S. Army Medical Research and Development Command | 138 | 2008-06-03 | 2020-03-17 |
| Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28), Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28) - Japanese Encephalitis, Hepatitis A | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 300 | 2008-03-01 | 2014-10-02 |
| Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age ChimeriVax™-JE, Japanese Encephalitis Inactivated Mouse Brain Vaccine - Japanese Encephalitis | Phase 2 | Completed | Sanofi | 96 | 2007-01-01 | 2012-08-27 |
| Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose - West Nile Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 208 | 2005-12-01 | 2016-04-14 |
| A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX ChimeriVax™-JE vaccine, JE-VAX® vaccine - Japanese Encephalitis | Phase 2 | Completed | Sanofi | 60 | 2005-05-01 | 2012-08-20 |
| Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine Live attenuated Japanese encephalitis virus, ChimeriVax™ diluent (Placebo) - Japanese Encephalitis | Phase 2 | Completed | Sanofi | 128 | 2004-11-01 | 2012-12-05 |
| Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) Live attenuated Japanese encephalitis virus; Yellow fever virus, Yellow fever virus; Live attenuated Japanese encephalitis virus - Japanese Encephalitis, Yellow Fever | Phase 2 | Completed | Sanofi | 108 | 2004-07-01 | 2012-09-20 |
| A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults Live attenuated Japanese encephalitis virus, then ChimeriVax diluent, ChimeriVax diluent, then Live attenuated Japanese encephalitis virus - Encephalitis, Japanese Encephalitis | Phase 2 | Completed | Sanofi | 202 | 2003-04-01 | 2012-07-16 |
| Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers Three 1 mL doses of Rabies vaccine and two JE vaccine, Three 0.5 mL doses of Rabies vaccine and two JE vaccine, Three 0.1mL doses of Rabies Vaccine and two JE vaccine - Rabies, Japanese Encephalitis | Phase 2 | Completed | Novartis | 200 | 2002-08-01 | 2008-06-10 |
| Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years. Tick-borne Encephalitis Vaccine - Tick-borne Encephalitis | Phase 2 | Completed | Pfizer | 2002-03-01 | 2015-05-21 |
Showing 20 of 24. Sign in to see all of them.
Encephalitis, Japanese (12) · Encephalitis, Tick-Borne (8) · Encephalomyelitis, Eastern Equine (2) · West Nile Fever (2) · Yellow Fever (2) · Encephalitis (1) · Hepatitis A (1) · Rabies (1) · Viremia (1)
Arbovirus Infections (24) · Brain Diseases (24) · Central Nervous System Diseases (24) · Central Nervous System Infections (24) · Central Nervous System Viral Diseases (24) · Encephalitis, Viral (24) · Infections (24) · Infectious Encephalitis (24) · Nervous System Diseases (24) · Neuroinflammatory Diseases (24) · RNA Virus Infections (24) · Vector Borne Diseases (24) · Virus Diseases (24) · Encephalitis (23)
Vaccines (3) · Desiccation (2) · Japanese Encephalitis Vaccines (2) · Saline Solution (2) · FSME-IMMUN vaccine (1) · Hepatitis A Vaccines (1) · Immunoglobulins, Intravenous (1) · Yellow Fever Vaccine (1)
Pfizer (5) · Sanofi (5) · Sanofi Pasteur, a Sanofi Company (3) · National Institute of Hygiene and Epidemiology, Vietnam (2) · Sormland County Council, Sweden (2) · U.S. Army Medical Research and Development Command (2) · Medical University of Vienna (1) · Novartis (1) · SK Bioscience Co., Ltd. (1) · Singapore General Hospital (1) · University of Liverpool (1)
United States (5) · Australia (4) · Austria (4) · Germany (4) · Finland (2) · Sweden (2) · Thailand (2) · Vietnam (2) · India (1) · Nepal (1) · New Zealand (1) · Singapore (1)
Robert Rivard, MD (2) · Thiem D Vu, MD., PhD. (2) · Ulrich Behre, MD (2) · Ajit Rayamajhi, MBBS, MD (1) · Anand Dubey, M.D (1) · Atul Shanker, Dr. (1) · Bakul B. Javadekar, M.D. (1) · Christina Forstner, MD (1) · Jenny Low Guek Hong (1) · Nancy L Abdou, MD (1) · Sam Nightingale, MRCP (1)
PMID 20856164, PMID 20864814, PMID 21148499, PMID 21150279, PMID 25872531, PMID 25886645, PMID 27686833, PMID 27815383, PMID 32728481, PMID 33899755, PMID 34452033, PMID 35101266